Janine Quinter
Medizinische Onkologie und Hämatologie · Dept. I
CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS
Sep 2, 2022Diese klinische Studie wird durchgeführt, um ein neues Prüfpräparat mit der Bezeichnung "CTL-002" zu testen. CTL-002 gehört zu einer Klasse von Medikamenten, die als monoklonale Antikörper bezeichnet werden. Antikörper sind vom Immunsystem hergestell...
Clinical Studies - Sep 2, 2022 - Sep 8, 2030
Completed
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Ac-cess
Aug 9, 2022SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support bio...
Clinical Studies - Aug 9, 2022 - Dec 31, 2027
Ongoing
Project leader: Appenzeller Christina
Members: Scherrer Julia, Quinter Janine
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Jul 8, 2022Die Immuntherapie hat die Behandlung vieler Krebsraten deutlich verbessert. Tumore verfügen jedoch über mehrere Mechanismen um eine Immunantwort zu begrenzen oder der Immunüberwachung zu entgehen. Diese Studie untersucht neuartige Wege, diese Barrier...
Clinical Studies - Jul 8, 2022 - Dec 31, 2025
Ongoing
Project leader: Hess Dagmar
Members: Aeschbacher Anette, Quinter Janine
ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)
Mar 3, 2022Diese klinische Studie wird durchgeführt, um ein neues Arzneimittel mit dem Namen ANV419 zu testen. Dieses neue Arzneimittel hat im menschlichen Körper eine Wirkung ähnlich Interleukin-2. Diese klinische Studie wird durchgeführt, um die Sicherheit...
Clinical Studies - Mar 3, 2022 - Mar 2, 2024
Automatically Closed
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
A Phase III, randomised, Open-Label, multicenter study evaluating the efficacy and safety of adjuvant GDC-9545 compared with physician's choice of adjuvant endocrine Monotherapy in patiens with Estrogen Receptor−Positive, HER2-NegativeEarly Breat Cancer
Mar 1, 2022Der Zweck dieser Studie ist es, die positiven oder negativen Auswirkungen von Giredestrant im Vergleich zu einer zugelassenen endokrinen Therapie (eine Behandlung, die Hormone blockiert oder entfernt) bei Patientinnen/Patienten mit Ihrer Art von Kreb...
Clinical Studies - Mar 1, 2022 - Jul 26, 2030
Ongoing
Project leader: Huober Jens
Members: Sennhauser Andrina, Quinter Janine
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Jan 13, 2022MK-1084 enthält einen chemischen Wirkstoff und hemmt gezielt das mutierte KRAS-G12C-Protein. Generell spielen RAS-Proteine in der Zellteilung und Zelldifferenzierung eine grosse Rolle und wenn diese Proteine zu stark aktiviert sind, kann das zu Krebs...
Clinical Studies - Jan 13, 2022 - Mar 2, 2027
Ongoing
Project leader: Weindler Susanne
Members: Donno Monica, Quinter Janine
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear mainte-nance in patients with newly diagnosed Acute Myeloid Leu-kemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Oct 13, 2021Das Ziel dieser Studie ist es, die Therapie einer akuten myeloischen Leukämie (AML) oder eines myelodysplastischen Syndroms mit erhöhter Anzahl an Leukämiezellen (MDS-EB2) zu verbessern. Wir möchten nun die Wirksamkeit und Sicherheit von Gilteritinib...
Clinical Studies - Oct 13, 2021 - Jul 26, 2028
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine
SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase il trial
Jun 24, 2021Standard of care for Extensive-Stage Disease (ED) Small Cell Lung Cancer (SCLC) as first-line treatment is 4 to 6 cycles of platinum based chemotherapy (carboplatin or cisplatin) in combination with etoposide. However, the outcome of the disease...
Clinical Studies - Jun 24, 2021 - Jun 28, 2027
Ongoing
Project leader: Früh Martin
Members: Demmer-Steingruber Ruth, Quinter Janine
Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial
Jun 8, 2021Despite advances in the clinical care of patients with DLBCL and in understanding the biology of this disease, cure rates have remained the same since the introduction of rituximab to CHOP chemotherapy, and RCHOP chemoimmunotherapy remains the standa...
Clinical Studies - Jun 8, 2021 - Dec 31, 2030
Ongoing
Project leader: Hitz Felicitas
Members: Harder Anja, Quinter Janine
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
Apr 14, 2021TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the ma...
Clinical Studies - Apr 14, 2021 - Dec 31, 2025
Ongoing
Project leader: Jörger Markus
Members: Kern Julia, Quinter Janine
MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
Mar 17, 2021The rationale for this study comes from preclinical models, in which lenvatinib decreased the tumor-associated macrophage (TAM) population, which is known as an immune-regulator in the tumor microenvironment. The decrease in TAM population was accomp...
Clinical Studies - Mar 17, 2021 - May 7, 2030
Ongoing
Project leader: Fischer Stefanie
Members: Donno Monica, Quinter Janine
A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Neoadjuvant And Adjuvant Tiragolumab Plus Atezolizumab, With Or Without Platinum-Based Chemotherapy, In Patients With Previously Untreated Locally Advanced Resectable Stage II, IIa, Or Select IIIb Non-Small Cell Lung Cancer
Feb 12, 2021Das Ziel dieser Studie ist es die Wirkungen, ob positiv oder negativ, von Tecentriq (Atezolizumab) und Tiragolumab mit oder ohne Chemotherapie bei Patienten, deren Lungenkrebs operiert werden kann, zu beurteilen. Es soll herausgefunden werden, ob und...
Clinical Studies - Feb 12, 2021 - Dec 31, 2026
Ongoing
Project leader: Fischer Stefanie
Members: Sennhauser Andrina, Quinter Janine
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients
Oct 7, 2020Diese Studie untersucht die Sicherheit und erste Wirksamkeit einer immunstimulierenden intratumoralen Laser-Wärmetherapie in Kombination mit dem Studienmedikament IP-001, welches in den Tumor injiziert wird. Alle Patienten in dieser Studie erhalten d...
Clinical Studies - Oct 7, 2020 - Dec 31, 2024
Ongoing
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
Vacuum assisted biopsy Immediately before Surgery as an Intra- or pre-Operative surrogate for patient response to Neoadjuvant chemotherapy for breast cancer (VISION I) A multicenter prospective feasibility trial
Aug 11, 2020Manche Patientinnen und Patienten mit Brustkrebs erhalten vor der Tumoroperation eine Chemotherapie, um den Tumor zu verkleinern. Manchmal wirkt diese Chemotherapie so gut, dass der Tumor nach der Chemotherapie mit bildgebenden Verfahren nicht mehr n...
Clinical Studies - Aug 11, 2020 - Dec 31, 2024
Ongoing
Project leader: Strub Christine
Members: Sennhauser Andrina, Quinter Janine
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Dec 18, 2019IDH1 or IDH2 mutations are each found in about 10% of AML – and specific inhibitors are approved or in development in this indication. The primary objective of this study is to compare event-free survival (EFS) between ivosidenib/enasidenib and pl...
Clinical Studies - Dec 18, 2019 - Jan 31, 2027
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine
ENIGMA: Open label, non-randomized, Phase IB study to character-ize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einig...
Clinical Studies - May 2, 2019 - Dec 31, 2024
Ongoing
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.
Oct 26, 2018In dieser Studie wird zum ersten Mal die Sicherheit und Wirksamkeit eines neuen Medikaments (Talidox) bei Menschen untersucht. Bei dem neuen Medikament handelt es sich um einen bekannten Wirkstoff, das Chemotherapeutikum Doxorubicin, welches in einer...
Clinical Studies - Oct 26, 2018 - Dec 31, 2026
Ongoing
Project leader: Hess Dagmar
Members: Harder Anja, Quinter Janine
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
Jun 3, 2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Clinical Studies - Jun 3, 2016 - May 31, 2026
Ongoing
Project leader: Silzle Tobias
Members: Quinter Janine
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
Oct 26, 2015Es handelt sich um eine randomisierte open label Phase III Studie. Die Patienten werden vom Hauptsitz der EORTC zentral im Verhältnis 1:1 für die Therapie mit Enzalutamid oder Enzalutamid (Standartbehandlung) und Ra223 (experi-mentelle Behandlung) r...
Clinical Studies - Oct 26, 2015 - Dec 31, 2030
Ongoing
Project leader: Rothermundt Christian
Members: Demmer-Steingruber Ruth, Quinter Janine
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)
Jul 7, 2014Background: Denosumab, a monoclonal antibody against RANK-Ligand has been shown to be superior to zoledronic acid in delaying time to a first on-study skeletal-related event (SRE) in patients with solid tumors, with no effects on disease progression...
Clinical Studies - Jul 7, 2014 - Dec 31, 2026
Ongoing
Project leader: Fischer Stefanie
Members: Sakic Miranda, Quinter Janine